Proposal to list and award market share for various wound care products in DHBs
PHARMAC is seeking feedback on a proposal to list and award market share for various wound care products in DHBs, as a result of a request for proposals issued on 15 September 2015 and the subsequent amendment issued on 7 October 2015.
This is the first time PHARMAC is proposing to award market share in a hospital medical devices category since PHARMAC started managing hospital medical devices in 2012. This proposal follows consultation, feedback and engagement with the sector on PHARMAC’s proposed approach to market share procurement for hospital medical devices. We proposed wound care would be the first category considered for market share procurement.
The proposed market share agreements are different to current PHARMAC hospital medical devices agreements. Market share agreements guarantee suppliers a portion of the DHB market in return for competitive pricing and quality products. This means that any DHB that uses the types of products for which a market share agreement has been awarded would be subject to certain restrictions.
We are proposing to introduce market share agreements to DHBs for a small group of relatively low risk clinical products. This will allow DHBs to start to benefit from some savings while setting the foundations for similar activity in other medical device categories that may offer greater savings.
Market share agreements are proposed for the following sub-categories:
- IV pressure pads
- Low adherent dressings with adhesive border
- Combine dressings (non-sterile)
- Combine dressings (sterile)
- Foam adhesive dressings (with and without border)
- Foam non-adhesive dressings
This is a brief overview only. For more detail, please see the link below.
Meaningful engagement with, and feedback from, a wide range of external stakeholders has played a major role in the development of this proposal. We want your feedback on the details of the proposal to ensure we make decisions on the basis of all relevant information.
Please provide your feedback on this proposal by Friday, 29 July 2016 to:
Device Category Manager
PO Box 10 254
Fax: 04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Background documents including PHARMAC’s approach to market share procurement consultation and feedback, the wound care RFP and the Wound Care Advisory Group (WCAG) minutes are linked below.
The minutes of the WCAG meetings held after the RFP had closed have not been published because they include commercially sensitive information in the context of the RFP evaluation process.